
RefleXion Medical
By leveraging positron emission tomography (PET), the gold standard in cancer imaging and staging in a novel way, RefleXion’s patented technology* causes tumors to continuously signal their location during radiotherapy.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor investor | €0.0 | round |
investor investor investor | €0.0 | round | |
investor investor investor investor investor | €0.0 | round | |
investor investor investor investor investor investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
investor | €0.0 Valuation: €0.0 | round | |
investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
investor | €0.0 | round | |
* | $105m Valuation: $550m | Late VC | |
Total Funding | 000k |
Related Content
RefleXion Medical is a pioneering company in the field of radiotherapy, focusing on advanced cancer treatment. The company has developed a breakthrough technology known as Biology-Guided Radiotherapy (BgRT), which uses signals emitted from cancer cells to guide high doses of radiation directly to tumors, even while they are in motion. This approach aims to maximize the impact on the tumor while minimizing damage to surrounding healthy tissue. RefleXion's technology is particularly significant for patients with stage four cancer, who are often not considered candidates for definitive radiotherapy due to the challenge of treating multiple tumors. By enabling the simultaneous treatment of multiple tumors in a single session, RefleXion is redefining the possibilities of radiotherapy. The company collaborates with other therapies such as chemotherapy, immunotherapy, and targeted drugs to provide a comprehensive treatment plan tailored to individual patient needs. RefleXion operates in the healthcare and medical technology market, serving oncology centers and hospitals. Its business model revolves around the sale and maintenance of its radiotherapy machines, as well as partnerships with pharmaceutical companies. Revenue is generated through the sale of equipment, service contracts, and collaborative agreements.
Keywords: radiotherapy, cancer treatment, BgRT, oncology, stage four cancer, multiple tumors, real-time tracking, chemotherapy, immunotherapy, targeted drugs.